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I. INTRODUCTION: 
This clinical guideline has been created to consistently improve health care services for injured 
workers by outlining the appropriate evaluation and treatment processes for the management of 
chronic pain which has been determined to be work related. The guideline should be used as a tool to 
guide health care providers of different professional disciplines to provide quality care to injured 
workers. The guideline is not intended to be a substitute for appropriate medical judgment, and is 
written to be broad enough to allow for a wide range of diagnostic and treatment modalities, and to 
purposely allow for philosophical and practice differences among professional disciplines of health 
care practitioners who provide care to injured workers with chronic pain.  It is expected that 
approximately 10% of cases may fall outside of this guideline and may be reviewed and approved on a 
case by case basis.  If objective clinical improvement is delayed or slower than expected, the treating 
provider must justify the necessity of continued care with a valid clinical rationale, with supporting, 
objective clinical findings.  Timeframes for specific interventions commence once treatments have 
been initiated, not on the date of injury.   
 
II. BACKGROUND:  
Chronic Pain represents a specific diagnosis which refers to pain which outlasts the expected duration 
of the healing time for tissue injury. Common clinical manifestations include persistent complaints of 
pain, impaired function, and symptoms of anxiety, depression, fear and anger.  Chronic pain may be 
associated with psychosocial problems and thus the treatment should include evidence-based 
psychological treatment when indicated.  The purpose of an intensive short-term treatment program is 
the reduction of pain, reduction of physical impairments, and behavioral management of chronic pain 
behaviors.  The goals are to: maximize the function of the injured worker in work-related activities 
and/or activities of daily living, optimize medical treatment and seek a balance between appropriate 
treatment of pain and safety in the use of opioids.  Patients receiving therapeutic treatments should be 
released or returned to duty during the rehabilitation period at the earliest appropriate time.  Continued 
treatment should be monitored using objective measures such as: return to work or maintaining work 
status, fewer work restrictions or performing activities of daily living, decrease in usage of ineffective 
medications, adjustment of effective medications, improved emotional status, and measurable 
functional gains such as increased range of motion or increase in strength.   
A cure for chronic pain may not be expected.  Management of chronic pain may be lifelong requiring 
repeat cycles of the chronic pain treatment plan.  A diagnosis of chronic pain or a recommendation for 
chronic pain treatment may be inappropriate when a patient has other conditions that may make 
treatment ineffective.  Treatment may be ineffective when a patient exhibits symptoms of exaggerated 
pain behavior, addictive behaviors, and factitious disorders.  
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III. HISTORY: 
A diagnosis of Chronic Pain should be considered if: 
 Pain has extended beyond the duration of expected tissue healing based on the history and physical 
examination by the treating practitioner. 
 Significant functional impairment persists in spite of apparent healing of underlying pathology as 
determined by the treating practitioner. 
 The recovery period exceeds the expected duration of treatment for the primary diagnosis without 
becoming eligible for another guideline. 
 Pain persists beyond 3 months from the date of injury.  
 
The absence of a diagnosis of “chronic pain” by the treating health care practitioner does not preclude 
the use of this treatment guideline if the aforesaid considerations exist.   
 
IV. INITIAL EVALUATION 
HISTORY AND PHYSICAL EXAMINATION 
Patient information should include medical and psychosocial history, mechanism of injury, pain 
history, medical management history, substance use/abuse, and other factors that may affect treatment 
outcome. Physical exam must be conducted. 
Personality/Psychosocial/Psychological Evaluation 
All patients who are diagnosed as having chronic pain should be referred for a psychosocial evaluation 
as well as concomitant interdisciplinary rehabilitation treatment whenever appropriate.  Initial exam to 
be performed by a psychologist with a PhD, PsyD, EdD credential, or Psychiatric MD/DO may 
perform the initial comprehensive evaluations. It is recommended that these professionals have 
experience in diagnosing and treating chronic pain disorders in injured workers. A clinical evaluation 
should be conducted and psychological functioning tests may be valuable.  When treatment involves a 
multidisciplinary approach, one primary medical practitioner should coordinate the care and monitor 
the treatment plan in conjunction with other health care specialists. 
                   
V. TREATMENT AND THERAPEUTIC NON-OPERATIVE PROCEDURES  
A. PHYSICAL MEDICINE 
Treatment modalities may be utilized sequentially or concomitantly depending on chronicity and 
complexity of the problems.  Services should not be duplicative.  The focus of treatment should be 
functional training and physical conditioning.  Functional improvement should be documented in order 
to justify providing ongoing physical medicine or other sequential treatment.   
 
1.  Physical Therapy--maximum 20 visits based on treatment plan. May include aquatic therapy.  
2.  Occupational Therapy--maximum 20 visits based on treatment plan. 
3.  Chiropractic Treatment--maximum 20 visits based on treatment plan. 
COMMONWEALTH OF MASSACHUSETTS 
DEPARTMENT OF INDUSTRIAL ACCIDENTS 
 
CHRONIC PAINTREATMENT GUIDELINE 
REVISED MAY 2016 
__________________________________________________________________________________ 
PAGE THREE 
 
 
4.  Work Conditioning/Work Hardening Program--maximum 20 visits, up to 4 hours/visit based on 
   treatment plan. This program allows for intensive physical therapy subsequent to the initial course 
   of physical therapy.  Must have a return to work goal.  Patient may be participating in the program 
     while working in a restricted capacity.   
5.  Acupuncture--Must be ordered by a licensed MD, DC, DO, PA, NP, or PT and performed by an    
     acupuncturist licensed in the state where the acupuncture service is provided.  Six (6) visits 
     allowed in first eight (8) weeks of acupuncture treatment.  Thereafter, the ordering practitioner  
     may request additional visits if there is documentation of objective improvement in functional 
activity or when the symptomatic benefit facilitates progression in the patient’s treatment          
program. Maximum visits are not to exceed sixteen (16) visits in twelve (12) weeks.  The     
ordering/treating practitioner cannot be the provider of the acupuncture service. 
6.  Surface EMG and Thermal Biofeedback-- Limited to treatment of chronic headaches.  To be  
     provided in conjunction with other psychosocial intervention, maximum 12 sessions. 
7.  Physical agents and modalities--maximum of 1 allowed per treatment session.   
8.  Special Tests 
     a. Functional/Work/Physical Capacity Evaluation. 
     b. Job Site Evaluation. 
     c. Vocational Assessment. 
     d. Work Tolerance Screening-- Initial evaluation and may monitor improvements every 3 to  
          4 weeks up to a total of 6 evaluations. 
9.  Orthotics/Prosthetics/Equipment  
 
B. DIAGNOSTIC AND THERAPEUTIC INJECTIONS 
Injection therapy should not begin before 6 weeks post injury in order to prevent the exclusion of 
effective conservative treatment. However, if the patient is unable to participate in rehabilitation 
because of severe pain, injection therapy should be allowed.  These injections are seldom meant to be 
“curative” and when used for therapeutic purposes they are employed in conjunction with other 
treatment modalities for maximum benefit.  Reassessment of the patient’s status in terms of functional 
improvement should be documented after each injection.  
 
Diagnostic Spinal Injections   
Maximum of 2 diagnostic injections, at least 2 weeks apart.  No more than 2 levels may be injected in 
a single session.  Patient response must be documented such that the diagnostic value of the procedure 
is evident to reviewers.  At a minimum, the provider should document patient response immediately 
following the procedure specifying any reduction or resolution of symptoms.  In general, relief should 
last for at least the duration of the local anesthetic used and should provide a minimum of 50% pain 
reduction as measured by a numerical pain index scale.  
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Therapeutic Spinal Injections 
May be used after initial conservative treatments have not provided significant pain relief or functional 
improvement. The purpose is to facilitate active therapy by providing short-tem relief through 
reduction of pain and inflammation. Active treatment, which patients should have had prior to 
injections, will frequently require a repeat of the sessions previously ordered and may be beneficial 
after the injection and significant pain reduction.  The benefits of the injections must be documented in 
the record including the degree of pain reduction, the duration of pain reduction, and change in 
function, if any. 
 
Epidural Steroid Injections: Must have radicular pain or radiculopathy.  A series of up to 3 injections 
may be given at least 2 weeks apart with fluoroscopic guidance. No more than 2 transforaminal levels 
may be injected in one session.  If there is not a minimum of 50% pain reduction as measured by a 
numerical pain index scale or documented functional improvement, similar injections should not be 
repeated.   Maximum of 2 series may be done in one year based upon the patient’s response to pain and 
function.   
 
Zygapophyseal (Facet) Injections: Facet injections or medial branch blocks must be done with 
fluoroscopic guidance.  Facet injections should not be performed at more than 2 joints per visit and 
may be repeated one time per year, if they result in a minimum of 50% pain reduction as measured by 
a numerical pain index scale or documented increased functional benefit for at least 3 weeks.    If the 
first set of injections does not provide a diagnostic response of a minimum of 50% pain reduction as 
measured by a numerical pain index scale or documented functional improvement, similar injections 
should not be repeated.  At least 3 weeks of functional benefit should be obtained with each therapeutic 
injection.  If the medial branch block technique is used, then a maximum of 4 sets of injections may be 
done per year.   
         
Rhizotomy for Facet Joint Pain: Must be done with fluoroscopic guidance.  If the medial branch blocks 
provide 80% or more pain reduction as measured by a numerical pain index scale within one hour of 
the medial branch blocks, then rhizotomy of the medial branch nerves, up to 4 nerves per side, may be 
done.  If the first medial branch block provides less than 80% but at least 50% pain reduction as 
measured by a numerical pain index scale or documented functional improvement,  the medial branch 
block should be repeated before a rhizotomy is performed.  If 50% or greater pain reduction is 
achieved as measured by the NPIS with two sets of medial branch blocks for facet joint pain, then 
rhizotomy may be performed.  Pain relief must last a minimum of 120 days in order to repeat the 
treatment.   
COMMONWEALTH OF MASSACHUSETTS 
DEPARTMENT OF INDUSTRIAL ACCIDENTS 
 
CHRONIC PAIN TREATMENT GUIDELINE 
REVISED MAY 2016 
__________________________________________________________________________________ 
PAGE FIVE 
 
 
Rhizotomy for Sacroiliac Joint Pain:  Must be done with fluoroscopic guidance.  Allowed if the 
anesthetic block of the L4,L5 dorsal rami and S1-S4 lateral branch nerves or a Sacroiliac joint injection 
provides a positive diagnostic response of 80% or more pain reduction as measured by a numerical 
pain index scale.  If the above block provides less than 80% but at least 50% pain reduction as 
measured by a numerical pain index scale or documented functional improvement, the sacral 
peripheral nerve injection should be repeated before a rhizotomy is done.  If 50% or greater pain 
reduction is achieved as measured by the NPIS with two sets of blocks (as outlined above) for the SI 
joint, then rhizotomy may be performed.  Pain relief must last a minimum of 120 days in order to 
repeat the treatment.  May be repeated a maximum of 3 times per year.     
 
Sacro-iliac Joint Injections: Must be done with fluoroscopic guidance.  Two injections per joint per 
year allowed with a diagnostic response.  If the first set of injections does not provide a diagnostic 
response of temporary and sustained pain relief substantiated by a minimum of 50% pain reduction as 
measured by a numerical pain index scale or significant documented functional improvement, similar 
injections should not be repeated.     
     
Therapeutic Neuromuscular Injections 
May be used after initial conservative treatments have not provided significant pain relief or functional 
improvement. The purpose is to facilitate active therapy by providing short-tem relief through 
reduction of pain and inflammation. Injections and active treatment/exercise should be done 
concurrently.  The benefit of the injections must be documented in the record including the degree of 
pain reduction, the duration of pain reduction, and any change in function. 
 
Trigger Point Injections:  A series of injections with a maximum of 4 visits within the series is allowed 
over twelve week period.  Visits should be at least 3 weeks apart.  A minimum of 50% pain reduction 
as measured by a numerical pain index scale or significant documented functional improvement is 
required in order to repeat the series.  Steroids should not be used in more than 2 visits of the series.  
Some patients may require 2 series of trigger point injections over a 1 year period. 
 
Botulinum Toxin Injections: May be useful in musculoskeletal conditions associated with muscle 
spasm, especially in the cervical area. There should be evidence of limited range of motion prior to the 
injection. May be useful in central neurological conditions that produce spasticity or dystonia (e.g., 
brain injury, spinal cord injury, or stroke).  Repeat injections allowed with a minimum of 50% pain 
reduction as measured by a numerical pain index scale or significant functional improvement.  There 
should be at least a 90 day interval between re-administration. No more than 4 injections per year.  
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C. PSYCHOSOCIAL 
Treatment is recommended as an important component in the total management of a patient with 
chronic pain and should be implemented as soon as the problem is identified.  Goal oriented treatment 
should be cognitive, behavioral or operant approaches provided by licensed mental health providers 
trained to treat patients with persistent pain.  Specific treatments have been shown to be effective in 
individual or group format. Treatment frequency is 1 to 2 times weekly for the first 8 weeks (excluding 
hospitalization, if required).  Thereafter, 2 to 4 times monthly with the exception of exacerbations 
which may require increased frequency of visits, not to include visits for medication management.  
Treatment duration is 2 to 6 months with a maximum of 6 to 12 months, not to include visits for 
medication management.  For select patients, longer supervised treatment may be required and, if 
further counseling beyond 6 months is indicated, functional progress must be documented.  Treatment 
should be part of an overall interdisciplinary treatment plan, and return to work must be a treatment 
goal if medically possible.  Due to the risk of major depression and anxiety, psychopharmacology 
consultation should be available.   
 
D. MEDICATIONS      
Control of chronic non-malignant pain often involves the appropriate use of various medications.  
Ongoing effort to gain improvement in activities of daily living, and social and physical function as a 
result of pain relief should be a primary goal with the use of any medication.  Consultation or referral to 
a pain specialist should be considered when the pain persists beyond the expected time for tissue healing 
of the injury. Consider consultation to a pain specialist if suffering and pain behaviors are present and 
the patient continues to request medication, or when standard treatment measures have not been 
successful or are not indicated.  Opioids may only provide limited pain reduction and improvement in 
function, and increase the risk of dependence and addiction. As such, other non-opioid/or non-
pharmacological options may be superior to opioids.  If opioids are used, they should be combined with 
nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate.  Before starting opioid 
therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic 
goals for pain and function, and should consider how opioid therapy will be discontinued if benefits do 
not outweigh risks. Clinicians should continue opioid therapy only if there is clinically meaningful 
improvement in pain and function that outweighs risks to patient safety. 
 
It is recommended that use of opioid analgesic and sedative hypnotic medications in chronic pain 
patients be used in a very limited manner, with total elimination desirable whenever clinically feasible 
and/or resolution of the underlying cause of the pain.  Tapering or a detoxification program may be 
necessary and this may include inpatient detoxification.  Medical management should be part of an 
overall interdisciplinary treatment plan and return to work must be a treatment goal if medically 
possible.  
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On-Going, Long-Term Opioid Management – Actions should include: 
A) Prescriptions from a single practitioner, and one pharmacy when possible. Clinicians should      
review the patient’s history of controlled substance prescriptions using state prescription drug       
monitoring program (PDMP) data to determine whether the patient is receiving opioid dosages or      
      dangerous combinations that put him or her at high risk for overdose. Clinicians should review     
      PDMP data when starting opioid therapy for chronic pain and periodically during opioid therapy 
      for chronic pain, ranging from every prescription to every 3 months.  The Massachusetts      
Prescription Monitoring Program may be accessed at www.mass.gov/dph/dcp/onlinepmp.   
B)  Ongoing review and documentation of pain relief, functional status, appropriate medication use, and 
side effects.  Visits initially at least every 2-4 weeks for the first 2-4 months of the trial, then at least 
once every 6-8 weeks while receiving opioids.  If there has not been an overall improvement in 
function, opioids should be tapered and discontinued. 
C)  Patient Physician Agreement – All patients on long term opioids must have a written, informed  
      agreement. The agreement should discuss side effects of opioids, results of use in pregnancy, 
      inability to refill lost or missing medication/prescription, withdrawal symptoms, requirement for  
      drug testing, necessity of tapering, and reasons for termination of prescription. 
D) A baseline initial drug screen should be performed before starting opioid therapy, and the use of 
random drug  screening at least twice and up to 4 times per year, or more if clinically indicated, for 
the purpose of improving patient care.      
E)  If more than two opioids are prescribed for long-term use; and/or the total daily dose of opioids is 
above 90 MME/day; and/or opioids with central nervous system depressants are prescribed, then a 
second opinion from a Pain Medicine Specialist is strongly recommended. 
F)  Inpatient treatment may be appropriate in complex cases as well as referral to a Pain Specialist. 
G)  Laboratory monitoring as indicated. 
H) The total daily dose of opioids should not be increased above 90 MME/day.  In some instances, the 
patient may benefit from a higher dose if there is documented objective improvement in function and 
pain, and a lack of significant opioid side effects.  
I) Multidisciplinary treatment including non-opioid pain medication and non-pharmacological     
therapies, including but not limited to home exercise, chiropractic treatment, physical therapy, and 
psychological treatment may be beneficial. 
J)  Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk 
factors for opioid-related harms. Clinicians should incorporate into the management plan strategies 
to mitigate risk, including considering offering naloxone when factors that increase risk for opioid 
overdose, such as history of overdose, history of substance use disorder, higher opioid dosages 
      (≥50 MME/day), or concurrent benzodiazepine use, are present.  
K) Clinicians should, if possible, offer or arrange evidence-based treatment (usually medication-     
assisted treatment with buprenorphine or methadone in combination with behavioral therapies) for     
patients with opioid use disorder.  Prescribing practitioners should be mindful of the impact of     
prescribing opioids relative to safety sensitive positions.  
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GENERAL GUIDELINES FOR OPIOID DISCONTINUATION AND TAPERING 
Patients should not be abandoned 
After determining that the failure of the pain treatment plan was not due to opioid under-dosing and/or 
inadequate medication time schedules, discontinue  opioids when:      
Pain resolution; 
Lack of functional improvement; 
Decrease in functioning; 
Aberrant drug screening result and/or diversion; 
Serious non-adherence; 
Intolerance or severe adverse side effects;  
Hyperalgesia; and 
Decreased effects from opioid. 
 
 Patients treated for acute pain who are opioid-naïve should generally require no tapering.  
 Patients with acute pain treated with continuous opioids over 50mg MED for longer than 3 
            weeks duration may benefit from brief tapering over three to seven days.   
 Tapering plan for patients treated with opioids for subacute and chronic pain varies            
depending on prior opioid dose and duration.    
 Consultation with an addiction/pain medicine specialist or behavioral health specialist with 
            expertise in pain management is recommended for complex patients.  
 Multidisciplinary treatment including non-opioid pain medication and non-pharmacological 
            therapies, including but not limited to home exercise, chiropractic treatment, physical therapy, 
            and psychological treatment may be beneficial during the tapering process. 
 
VI. TREATMENT NOT ALLOWED 
    1. Physical agents and modalities not allowed as the only treatment procedure. 
    2. Duplication of any services for patients being treated by more than one discipline. 
3. Repeat diagnostic studies without a significant change in symptoms and/or objective clinical 
    findings.  
 
VII. PATIENT EDUCATION  
Includes encouraging the patient to take an active role in establishing functional outcome goals and 
information regarding the adverse effects of inactivity.  Return to work is strongly encouraged and 
should be discussed with patient.  
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VIII. MAINTENANCE MANAGEMENT 
Excludes exacerbations which may require more aggressive treatment. 
A. Psychological/Psychopharmacological Management: maintenance duration one visit per month.  
B. Medication and Injection Management: should be linked to maintaining and/or improving function, 
not just pain control. 
C. Physical Medicine Management: consisting of one visit per month and should be linked to 
maintaining and/or improving function, not just pain control. 
 
 
 
LINKS:  www.agencymeddirectors.wa.gov/opioiddosing.asp 
                www.massmed.org/opioid-guidelines/ 
                www.cdc.gov/drugoverdose/prescribing/guideline.html 
 
 
SAMPLE 
PATIENT UNDERSTANDING FOR OPIOID TREATMENT  
 
 
Patient Name: ___________________________  
 
Doctor Name: ___________________________ 
 
 
I am taking a pain medicine called OPIOIDS to help reduce my pain. 
 
I agree (the patient must initial each box to show agreement): 
 
I will take my pain medicine exactly the 
way my doctor tells me to. That means I 
will take the right amount of pain 
medicine at the right time. 
 
I will tell my doctor about any new 
medical problems. 
 
I will tell my doctor about all medicine I 
take, and will tell my doctor if I am given 
any new medicines. 
 
I will tell my doctor if I treat with another 
medical provider, or if I go to the Emergency 
Room. 
 
I will only get my pain medicine 
prescription from this doctor. My 
doctor's name is listed on the top of this 
page. 
 
If my doctor is away, I will only get 
medicine from the doctor who is in 
charge while my doctor is away. 
 
I will only get my pain medicine from one 
pharmacy (drug store). 
 
I will follow my doctor’s directions about 
therapy, exercises and physical things to 
do so I can learn to function with my pain 
and have the best outcome. 
 
I understand the dangers to myself and others 
when driving and participating in safety 
sensitive activities while taking opioids. 
 
 
When I am asked, I will get lab tests to 
see if I am taking my medicines the right 
way. 
 
If the lab tests show that I am not taking 
the medicines the way I should, my 
doctor may cut down or stop my 
medicine or send me to a specialist or 
special program to help care for me. 
 
I will store my pain medicine in a safe 
place where other people cannot take it. 
 
I will keep my scheduled appointments. If 
I must miss an appointment, I will call my 
doctor to cancel at least 24 hours before 
the appointment. 
 
My doctor may stop giving me pain 
medicine if: 
I do not follow this agreement. 
The pain medicine is not helping me. 
I’m not meeting my goals in active therapy. 
My pain or my functions do not improve. 
I have bad side effects from the pain medicine. 
I become addicted to the pain medicine. 
I give or sell the pain medicine to someone else. 
 
I am not pregnant and I will call my doctor as  
soon as possible if I think I may be pregnant. 
 
   I understand that alcohol use when taking 
   opioid medication is extremely dangerous.   
   I will not take any other drugs unless I am told 
   to do so by my doctor. 
 
Patient Signature:                                                                                           Date: 
 
I attest that this form was reviewed by me with the patient and all questions were answered. 
Prescriber Signature:                                                                                     Date: 
Adapted from New York State Workers’ Compensation Board 
New York Non-Acute Pain Medical Treatment Guidelines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLE 
 
PATIENT INFORMED CONSENT FOR OPIOID TREATMENT 
 
 
Patient Name: ________________________ 
Doctor Name: ________________________ 
 
I plan to take a pain medicine called OPIOIDS.  This pain medicine may help reduce my pain but it may 
also cause some serious problems.  The problems may be worse if I mix the pain medicine with alcohol 
or other drugs. 
I understand that the pain medicine I will be taking may cause serious problems including: 
Confusion 
Poor judgment 
Nausea/Vomiting 
Stomach ache 
Constipation (hard stools that may be painful to push out). 
Sleepy or drowsy feeling 
Poor coordination and balance (such as feeling unsteady, tripping, and falling) 
Slow reaction time 
Slow breathing or I can stop breathing - which could cause me to die 
More depression (such as feeling sad, hopeless, or unable to do anything) 
Dry mouth 
Increased feeling of pain (hyperalgesia) 
Addiction (it may be very hard to stop taking the pain medicine when I'm ready to quit) 
For men: the pain medicine may lead to less interest in sex and poor sexual performance 
For pregnant women, the pain medicine may hurt my unborn child and may cause my child 
        to be born addicted to the pain medicine 
 
 I will tell my doctor if I have any of the problems listed here. 
 I understand there may be other problems caused by the pain medicine, in addition to the problems 
listed here. 
 I understand that these problems may get better when I stop taking the pain medicine. 
 I understand that my physician will be checking the Prescription Monitoring Program as required by 
state law. 
 My doctor has reviewed the serious problems that this pain medicine may cause with me. 
 My doctor has answered all questions that I have about this pain medicine and the serious problems 
it may cause. 
 
Patient Signature:      Date: 
 
I attest that this form was reviewed by me with the patient and all questions were 
answered. 
 
Prescriber Signature:       Date     
 
Adapted from New York State Workers’ Compensation Board 
New York Non-Acute Pain Medical Treatment Guidelines 
 
 
